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1. Introduction
Autophagy is a basic cellular event conserved in all 
eukaryotes from yeast to man. It serves as an intracellular 
quality-control mechanism recycling long-lived or 
misfolded/aggregate-prone proteins and damaged 
organelles, such as mitochondria. Moreover, under 
stress conditions, autophagy is upregulated in order to 
generate building blocks that are necessary for cellular 
survival (Kuma and Mizushima, 2010; Rabinowitz and 
White, 2010). Therefore, autophagy mainly serves as 
a stress-adaptation and survival mechanism (Su et al., 
2013). However, under certain conditions, autophagy was 
reported to contribute to programmed cell death either 
indirectly through crosstalk mechanisms with apoptosis 
(Gozuacik and Kimchi, 2004; Oral et al., 2012; Rubinstein 
and Kimchi, 2012) or directly through autophagic cell 
death (Gozuacik and Kimchi, 2007). 
Abnormalities of autophagy were reported in various 
diseases, including neurodegenerative diseases, lysosomal 
storage diseases, infections, metabolic diseases, and 
ischemia/reperfusion injury (Schneider and Cuervo, 
2014). Cancer is no exception. The roles of autophagy in 
cancer formation, growth, ischemia resistance, metabolic 
changes, neovascularization, and even metastasis and 
tumor dormancy were reported (Gewirtz, 2009; Guo et al., 
2013b; Murrow and Debnath, 2013). Moreover, autophagic 
capacity was shown to significantly affect responses of 
cancer cells to anticancer agents and radiation (Eberhart 
et al., 2013). In this review we will mainly focus on the role 
of autophagy in cancer formation and cancer therapy. 
2. Basic mechanisms of autophagy
There are 2 major catabolic mechanisms in mammalian 
cells: the ubiquitin-proteasome system and the autophagy-
lysosomal system. Proteasomes degrade mainly short-
lived and soluble proteins following their regulated 
ubiquitinylation (Hershko and Ciechanover, 1998). In 
contrast, lysosomal pathways rely on the delivery of 
cytosolic contents into the lumen of the organelle, an 
event that is followed by their degradation by specific 
hydrolases. Here, ingested cytoplasmic targets might be 
various. The list includes long-lived proteins, old and 
damaged organelles (e.g., mitochondria and peroxisomes); 
misfolded, mutant, and/or aggregated proteins; and 
pathogens such as bacteria, viruses, and parasites. So far, 
3 subtypes of autophagy have been described in mammals: 
microautophagy, chaperone-mediated autophagy (CMA), 
and macroautophagy (Klionsky and Schulman, 2014).
Microautophagy proceeds through direct invagination 
of the vacuolar/lysosomal membrane and engulfment of 
nearby cytosolic materials (Uttenweiler et al., 2005). In 
addition to cargo digestion, microautophagic vacuoles 
also contribute to the maintenance of organelle size and 
membrane composition (Mijaljica and Devenish, 2011).
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CMA is an autophagic pathway allowing selective 
degradation of a subset of soluble proteins in lysosomes. 
During CMA, proteins containing the recognition 
and targeting motif KFERQ are selectively directed to 
lysosomes by a chaperone complex, consisting of HSC70 
(heat shock cognate of the HSP70 family) and its co-
chaperones. On lysosomal membranes, interaction with 
lysosome-associated membrane protein LAMP2A allows 
translocation into the lumen of the organelle (Massey et 
al., 2006). CMA plays a crucial role in the elimination 
of oxidized proteins and misfolded proteins, and it 
contributes to starvation responses (Kaushik and Cuervo, 
2012).
Macroautophagy (autophagy herein) is the major 
cellular autophagy pathway. It involves the engulfment 
of cytosolic cargo by double-membrane structures called 
isolation membranes that eventually close to form vesicles 
called autophagosomes or autophagic vesicles. Fusion of 
the outer membrane of autophagosomes with lysosomal 
membranes results in the delivery of autophagy cargos 
into the lysosome lumen and formation of autolysosomes. 
Hydrolases residing there degrade cargo contents to their 
building blocks, allowing their recycling back to the 
cytosol (Klionsky, 2007). 
There are also selective and nonselective types of 
autophagy. For example, while starvation-induced 
autophagy is generally considered as a nonselective form 
of autophagy, engulfment of organelles (mitophagy, 
pexophagy, ribophagy, ER-phagy), protein aggregates 
(aggrephagy), lipid droplets (lipophagy), and pathogenic 
invaders (xenophagy) occur in a selective way (Beau et 
al., 2008; van der Vaart et al., 2008; Kraft et al., 2009). 
Selective autophagy receptors include p62/SQSTM1 
(sequestosome  1), NDP52 (nuclear domain 10 protein 
52), NBR1 (neighbor of BRCA1 gene 1), BNIP3L (BCL2/
adenovirus E1B 19-kD protein-interacting protein 3-like), 
and OPTN (optineurin) (Shaid et al., 2013).
Autophagy can be induced by several factors such as 
starvation, hypoxia, or pathogens (Levine and Kroemer, 
2008; Mizushima and Levine, 2010; White et al., 2010; 
Wong and Cuervo, 2010). Autophagy proteins were initially 
identified in yeast during genetic studies, and at least 35 
of them have been functionally analyzed (Nakatogawa et 
al., 2009). The basic autophagy system was shown to be 
preserved in mammals. Most of the autophagy-related 
(or ATG) genes play a role during autophagosome 
nucleation, expansion, vesicle closure, and finally fusion 
with lysosomes and degradation (Mizushima et al., 2011). 
We will now introduce major stages of autophagy and 
summarize important molecular events involved in their 
regulation. 
2.1. Autophagosome nucleation
The mTORC1 protein kinase complex is the central nutrient 
sensing pathway in cells and a key regulator of autophagy 
(Ravikumar et al., 2004). Under nutrient-rich conditions, 
mTOR kinase regulates the phosphorylation of autophagy 
proteins ULK1/2 (UNC51-like kinase 1, mammalian 
homolog of yeast Atg1) and ATG13, and blocks autophagy 
(Figure 1). Stress conditions including hypoxia and growth 
factor or nutrient deprivation lead to the inactivation of the 
mTOR kinase, resulting in the activation of ULK1/2. This 
event is followed by a direct phosphorylation of ATG13 
and FIP200 (FAK family kinase-interacting protein, 200 
kDa) by ULK1/2 and stimulation of autophagy. The active 
ULK1/2 complex (ULK1/2-ATG13-FIP200-ATG101) 
then translocates to autophagosome nucleation centers 
and triggers consecutive stages. 
Another key autophagy complex is the 
phosphatidylinositol 3-kinase (PI3K) complex. In the 
mammalian system, this complex is composed of ATG14L 
(also known as ATG14 and Barkor), BECN1 (Beclin 1, yeast 
Atg6 ortholog), hVPS34 (vacuolar protein sorting protein 
34-VPS34-homolog), and hVPS15 (Figure 1) (Itakura et al., 
2008; Sun et al., 2008; Zhong et al., 2009; Matsunaga et al., 
2010). In the PI3K complex, hVPS34 is the kinase and its 
activity and localization is controlled by other components 
of the complex. For example, ATG14L was shown to recruit 
the complex onto the outer leaflet of the endoplasmic 
reticulum (ER) membranes. BECN1 is an important 
regulator of hVPS34 activity. In fact, PI3K complex activity 
is responsible for the accumulation of autophagy-related 
lipid molecules, namely phosphatidylinositol 3-phosphate 
(PI3P), in autophagosome initiation/nucleation sites. PI3P 
islands that form on the outer membrane leaflet of the ER 
serve as landing pads for the recruitment of autophagy 
effectors containing phosphoinositide-binding domains, 
such as FYVE finger domains or PH domains (for 
example, WIPI/Atg18 proteins). Additionally, AMBRA1 
(activating molecule in BECN1-regulated autophagy), 
UVRAG (UV irradiation resistance-associated gene), and 
BIF1 (endophilin B1) were shown to regulate the complex, 
whereas RUBICON (run domain- and cysteine-rich 
domain-containing BECN1-interacting protein) protein 
and antiapoptotic BCL2 (B-cell leukemia 2) proteins 
including BCL2, BCLXL/BCL2L1, and MCL1 were 
reported as inhibitors (Funderburk et al., 2010). Activation 
of ULK1/2 was reported to be important for the localization 
of the PI3K complex to autophagic membranes, placing 
the ULK1/2 complex upstream of the PI3K (Matsunaga 
et al., 2010). Additionally, AMBRA1 was shown to release 
a fraction of the PI3K complex from its association with 
dynein and allow its localization to autophagosomal sites 
in a ULK1/2-dependent manner (Mizushima et al., 2011).
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2.2. Autophagosome expansion and closure
Two ubiquitylation-like systems are known to mediate 
autophagosome expansion: the Atg12-Atg5 conjugation 
system, and the microtubule-associated protein 1 light 
chain 3 (Atg8 in yeast and MAP1LC3 or shortly LC3 in 
mammals) lipidation system (Figure 1) (Kirisako et al., 
2000; Mizushima et al., 2001). In the first system, Atg12 
is activated by Atg7 (E1-like enzyme), then transferred 
to Atg10 (E2-like enzyme). Finally, Atg12 is covalently 
conjugated to the Atg5 protein (Mizushima et al., 2001). 
Subsequently, the Atg12-Atg5 conjugate interacts with 
Atg16 (ATG16L1 in mammals) to form a complex of 
higher molecular weight (Figure 1) (Fujita et al., 2008). In 
the yeast system, the Atg12-Atg5-Atg16 complex (ATG12-
ATG5-ATG16L1 complex in mammals) is mainly localized 
to the surface of autophagosomes, and it dissociates from 
membranes following autophagic vesicle completion 
(Mizushima et al., 2001; Itakura and Mizushima, 2010). 
In the second system, in order to expose a glycine 
residue at its C terminal, LC3 protein is cleaved by ATG4B 
proteins soon after its synthesis. Processed protein stays in 
the cytosolic free form called LC3-I. Subsequently, LC3-I is 
activated by ATG7 (E1-like enzyme), transferred to ATG3 
(E2-like enzyme), and covalently linked to a lipid molecule, 
namely phosphatidylethanolamine (PE). The lipid-
conjugated LC3 form is called LC3-II and it is localized 
both on isolation membranes and autophagosomes (Satoo 
et al., 2009). Hence, demonstrations of LC3 lipidation 
and LC3-I to LC3-II conversion, as well as recruitment 
of cytosolic LC3 to autophagosomes, are widely used 
as reliable markers of autophagic activity. The ATG12-
ATG5-ATG16L1 complex is thought to act as an E3-like 
enzyme for LC3 lipidation, creating a direct link and 
interdependency between the 2 systems (Otomo et al., 
2013). LC3 lipidation is necessary for the elongation and 
completion of autophagic vesicles. Moreover, LC3 proteins 
Figure 1. Key morphological steps of autophagy in mammals. After mTOR inhibition (for example, with energy depletion, 
starvation, or hypoxia), the autophagy process begins with the nucleation of the isolation membrane. The 2 ubiquitin-like 
conjugation systems ATG16L1-ATG5-ATG12 and LC3-II participate after their activation in the expansion of the double 
membrane and the closure of the isolation membrane. Once it is completed, the structure is called an autophagosome. In 
mammalian systems, the autophagosome may fuse with a late endosome to form an amphisome, or it may fuse directly 
with a lysosome to form an autolysosome. Once the cargos are degraded, the products are released to the cytosol to be 
reused by the cell. 
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that are located in the inner membrane of autophagosomes 
serve as anchors for selective autophagy receptors, such as 
p62/SQSTM1, helping the recruitment of cargo proteins. 
GABARAP (GABA-A receptor-associated protein), 
GABARAPL1 (GABA-A receptor-associated protein-
like protein 1), and GABARAPL2/GATE16 (GABA-A 
receptor-associated protein-like protein 2) are other 
homologs of LC3 in mammals, and specific roles of these 
proteins and functional overlap between them are under 
investigation.
2.3. Fusion with lysosomes and degradation
In order to recycle cargo including long-lived proteins or 
damaged organelles, and to provide the cell with nutrients 
under stress conditions, autophagosomes fuse with late 
endosomes or lysosomes and lead to the “digestion” of 
structural constituents into their building blocks (for 
example, protein macromolecules are digested into amino 
acid building blocks) (Figure 1). Vesicular structures that 
are formed by autophagosome-lysosome fusion are called 
autolysosomes. Several proteins play a role during fusion 
events, including lysosomal membrane proteins such as 
the V-ATPase complex and LAMPs (lysosomal-associated 
membrane proteins) (Eskelinen et al., 2003) and small 
GTPases such as RAB7 (Ras-associated protein 7), 
RAB22, and RAB24 (Bucci et al., 2000; Kauppi et al., 2002; 
Munafo and Colombo, 2002). Additionally, ATG binding 
proteins such as UVRAG and cytoskeletal components, 
especially microtubules that direct autophagosomes 
towards lysosomes, were shown to be important for fusion 
(Jahreiss et al., 2008). SNARE (soluble N-ethylmaleimide-
sensitive factor attachment protein receptor) proteins 
also play an important role (Fader et al., 2009). Upon 
induction of autophagy, Stx17 (syntaxin17) is recruited to 
completed autophagosomes and interacts with cytosolic 
Qbc-SNARE SNAP (synaptosomal-associated protein)-29 
and the SNARE proteins VAMP7 (vesicle-associated 
membrane protein 7) or VAMP8, which are located on 
lysosomal membranes. This process drives the fusion 
between the outer membrane of autophagosomes with 
lysosome membranes (Itakura et al., 2012). Lysosomal 
lumen that is packed with lysosomal hydrolytic enzymes, 
including cathepsin proteases and lipases, degrades both 
autophagosome inner membranes and cargos, a process 
that is followed by recycling of digested constituents back 
to the cytosol.
3. Regulation of autophagy
3.1. Regulation of autophagy by signaling pathways
3.1.1. mTOR pathway
Various signals including growth factor signals, amino 
acids, and energy status are integrated by mTOR complexes 
(Ravikumar et al., 2004). mTOR kinase takes part in 2 
functional complexes, namely mTORC1 and mTORC2. 
The former complex is a major regulator of autophagy, and 
the latter mainly regulates cytoskeleton reorganization and 
migration. The mTORC1 complex is sensitive to the drug 
rapamycin, and it consists of the mTOR protein kinase, 
RAPTOR (regulatory associated protein of mTOR), 
mLST8/GβL, and PRAS40 (proline-rich Akt substrate of 
40 kDa) (Kim et al., 2003). 
As explained above, mTORC1 controls the formation 
of autophagy-related proteins complexes containing 
ULK1/2 and ATG13 (Jung et al., 2009). Indeed, inhibition 
of mTORC1 leads to an increase in ULK1/2 kinase activity, 
leads to the phosphorylation of ATG13 and FIP200, and 
triggers activation of autophagy (Hosokawa et al., 2009).
3.1.2. AKT/PKB pathway
Binding of growth factors or hormones such as insulin to 
receptors on the cell surface activates class I PI3K proteins. 
Activated PI3K proteins convert phosphatidylinositol-
4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-
triphosphate (PIP3) and recruit AKT/PKB to the plasma 
membrane. Active AKT/PKB contributes to cell growth 
by enhancing protein translation through mTOR-related 
phosphorylation and activation of downstream ribosomal 
protein S6 kinase, 70 kDa (RPS6KB/P70S6K), and 
phosphorylation of translation initiation factor 4EBP1 
(EIF4EBP1) and others (Klionsky et al., 2005). AKT/
PKB-mediated stimulation of mTORC1 activity results in 
autophagy inhibition.
A well-studied connection between AKT/PKB and 
mTOR is dependent on the TSC1/2 proteins. The TSC1/
TSC2 complex negatively regulates mTORC1 through 
inactivation of the mTOR-activator RHEB proteins 
(Guertin and Sabatini, 2007). AKT/PKB was shown to 
directly phosphorylate TSC2 and induce inactivation of 
the TSC1/TSC2 complex, relieving mTOR from RHEB-
dependent repression. 
Recently, an AKT/PKB-mediated phosphorylation 
of the autophagy protein BECN1 was reported to inhibit 
autophagy through sequestration of the protein by a 14-
3-3/vimentin intermediate filament complex (Wang et al., 
2012). 
3.1.3. AMPK (AMP-activated kinase)
The LKB1-AMPK pathway links metabolic status to cell 
growth control by sensing intracellular energy levels in 
cells (Shackelford and Shaw, 2009). In mammalian cells, 
AMPK activity is important for stress responses, including 
starvation responses (Meley et al., 2006). Increased 
AMP/ATP ratio reflecting a deficit in cellular energy 
status is a major signal that activates AMPK (Corradetti 
et al., 2004). Active AMPK inhibits mTORC1 signaling 
by interfering with the activity of the GTPase RHEB 
(Meijer and Codogno, 2004) and by activating eEF2-
kinase, which controls protein translation (Wu et al., 
2006). RHEB inactivation was shown to be a result of 
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TSC2 phosphorylation by AMPK, an event that stimulates 
TSC2 activity and that turns off mTORC1, activating 
autophagy (Inoki et al., 2003). AMPK can also stimulate 
autophagosome formation by phosphorylating and 
activating ULK1 (Egan et al., 2011; Kim et al., 2011).
3.1.4. BECN1 and the PI3K complex
BECN1 is an important regulator of autophagy. It is a 
component of the PI3K complex that plays a role during the 
initiation/nucleation phase of autophagosome formation. 
In fact, as mentioned previously, BECN1 regulates 
hVPS34 PI3K activity and PIP3P levels in autophagosome 
nucleation sites. Strikingly, antiapoptotic proteins of the 
BCL2 family, including BCL2, BCLXL, and MCL1, were 
shown to bind BECN1 through its BH3 (BCL2 homology 
domain 3) domain and to inhibit autophagy (Pattingre 
et al., 2005). BECN1-BCL2 protein interaction may be 
interrupted as a result of the phosphorylation of BCL2 
proteins by the stress kinase JNK-1 (c-Jun N-terminal 
kinase 1) (Wei et al., 2008). Inversely, DAPK (death-
associated protein kinase) can phosphorylate BECN1, 
reducing its BCL2 protein binding affinity (Zalckvar et 
al., 2009). Similarly, proapoptotic proteins BAD and BAX, 
and BH3 mimetics, led to the dissociation of BECN1-
BCL2 complexes (Maiuri et al., 2007; Luo and Rubinsztein, 
2010). 
3.2. Regulation of autophagy through transcriptional 
and posttranscriptional mechanisms
3.2.1. NFKB 
Nuclear factor kappa-B (NFKB) is a family of transcription 
factors that are involved in a variety of biological responses 
ranging from immune responses and inflammation to 
cancer (Karin, 2006). NFKB was shown to have a dual 
role in autophagy regulation. The promoter region of 
BECN1 was reported to contain an NFKB binding site 
(Copetti et al., 2009), and p65/RelA from the NFKB 
family upregulated BECN1 expression and induced 
autophagy in HEK293 and U2OS cells (Copetti et al., 
2009). In contrast, NFKB activation reduced autophagy by 
inhibiting BECN1 and ATG5 expression in macrophages 
(Schlottmann et al., 2008). Moreover, inhibition of NFKB 
was shown to potentiate starvation-induced autophagy in 
myelodysplastic syndrome cells (Fabre et al., 2007). Hence, 
the NFKB system seems to activate cell-type-dependent 
signals that lead to opposing outcomes in autophagy 
activation.
3.2.2. HIF1
The transcription factor HIF1 (hypoxia-inducible factor 
1) is a master regulator of gene expression under hypoxic 
conditions (Manalo et al., 2005). Hypoxia-mediated 
activation of HIF1 induced autophagy-related BH3 domain 
proteins BNIP3 (BCL2/adenovirus E1B 19-kDa protein-
interacting protein 3) and BNIP3L (BCL2/adenovirus E1B 
19-kDa protein-interacting protein 3-like) proteins (Bellot 
et al., 2009). BNIP3 and BNIP3L could bind to BCL2 and 
disturb BECN1-BCL2 protein interaction. BCL2-free 
BECN1 was then able to activate autophagy.
3.2.3. FOXO proteins
In response to growth and insulin stimulation, 3 proteins 
of the FOXO (Forkhead box O) family of transcription 
factors, namely FOXO1, FOXO3, and FOXO4, are 
regulated by AKT phosphorylation. If AKT is blocked, 
FOXO proteins are translocated into the nucleus and 
transactivate their target genes (Salih and Brunet, 2008). 
FOXO3 can especially induce the expression of several 
autophagy genes, such as LC3, GABARAPL1 BNIP3, and 
BNIP3L (Mammucari et al., 2007).
3.2.4. p53
The p53 transcription factor is defined as the guardian 
of genome, and it is one of the key tumor suppressor 
proteins. p53 prevents oncogenic formation by 
orchestrating pathways including DNA damage responses, 
cell cycle, apoptosis, and oncogene-related proliferative 
pathways (Vousden, 2009). Recent studies implicated 
p53 in autophagy regulation. Under stress conditions, 
p53, accumulated in the nucleus, transactivated several 
autophagy modulating genes such as DRAM (damaged-
regulated autophagy modulator) and TIGAR (TP53-
induced glycolysis and apoptosis regulator). DRAM was 
shown to stimulate accumulation of autophagosomes 
(Crighton et al., 2006) while, TIGAR inhibited autophagy 
through modulation of the glycolytic pathway and 
intracellular reactive oxygen species (ROS) levels 
(Bensaad et al., 2009). p53 also has a cytosolic fraction, 
and, interestingly, the cytoplasmic form of p53 had an 
inhibitory effect on autophagy (Tasdemir et al., 2008).
3.2.5. ER-stress-related responses
Imbalances of cellular calcium metabolism, transfer 
of mutant and/or abnormal proteins into the lumen, 
glycosylation problems, hypoxia, and so on cause 
accumulation of unfolded proteins in the ER and stimulate 
ER-specific stress pathways called the unfolded protein 
response mechanism or the ER-stress response. Among 
these stress response mechanisms, phosphorylation of 
the translation initiation factor eIF2α by PERK is a key 
event that turns off cap-dependent protein translation. 
However, stress-specific transcriptions factors such as 
ATF4 (activating transcription factor 4), ATF6 (activating 
transcription factor 6), XBP1 (X box-binding protein 
1), and CHOP (CCAAT-enhancer-binding protein 
homologous protein) are activated under these conditions. 
ER-stress response-related transcription factors including 
ATF4 and CHOP were involved in the upregulation of 
autophagy proteins such as LC3 and ATG5 and helped 
sustain autophagy responses under continuous stress 
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conditions (Kouroku et al., 2007; Rouschop et al., 2010). 
Additionally, calcium release from the ER during stress 
was reported to activate autophagy activation by the death-
inducing kinase DAPK (Gozuacik et al., 2008). 
3.2.6. Posttranslational modifications of autophagy 
proteins 
Autophagy proteins undergo various posttranslational 
modifications including phosphorylation, oxidation, 
acetylation, and proteolytic cleavage. For example, during 
starvation-induced autophagy, ATG4A and ATG4B were 
oxidized from their cysteine residue (Scherz-Shouval et al., 
2007). ATG5, ATG7, LC3, and ATG12 were deacetylated 
(Lee and Finkel, 2009) and ATG5, ATG7, and BECN1 were 
shown to be cleaved by calpain (Yousefi et al., 2006; Kim 
KW et al., 2008; Xia et al., 2010). Moreover, Atg4D, ATG3, 
and BECN1 were substrates for caspases (Betin and Lane, 
2009; Luo et al., 2010; Oral et al., 2012). The majority of 
these modifications were shown to modulate autophagic 
responses of cells. 
3.2.7. microRNA (miRNA) regulation of autophagy
miRNAs are small, endogenous noncoding RNA molecules 
involved in the posttranscriptional regulation of mRNAs, 
regulating protein levels. miRNA can bind specific 
response elements found in noncoding regions of at least 
dozens of mRNAs. In this way, miRNAs control stability 
and translation mRNAs, reshape protein expression 
profiles, and modulate and coordinate a number of 
important biological events, including cell proliferation, 
differentiation, and death. Recent studies underlined 
the importance of miRNA-related control of autophagy. 
miRNAs including MIR30A, the MIR376 family, and 
MIR181A were shown to target key autophagy proteins in 
various stages of autophagosome formation and control 
autophagic responses under various stress conditions 
(Zhu et al., 2009; Korkmaz et al., 2012; Korkmaz et al., 
2013; Tekirdag et al., 2013). The list of autophagy-related 
targets of miRNAs is growing and it includes important 
autophagy proteins ATG4, ATG5, and BECN1 (Tekirdag 
et al., 2014).
4. Role of autophagy in cancer
Accumulating evidence in the literature indicates that 
abnormalities of autophagy play a role in cancer formation 
and development. However, the exact nature of this link 
between autophagy and cancer seems to be context-
dependent. Figure 2 summarizes the role of autophagy in 
the early versus late stages of cancer. In early stages involving 
cancer formation, autophagy plays a tumor-suppressor 
role through degradation of dysfunctional organelles 
such as mitochondria, limitation of ROS production 
and prevention of damaged DNA accumulation, and 
prevention of genomic instability (Mathew et al., 2009b). 
However, at later stages, and especially in some contexts 
(e.g., oncogenic K-RAS pathway activation), autophagy 
acts as a survival pathway supporting tumor growth under 
unfavorable metabolic conditions (scarce nutrient supply, 
hypoxia, and high energy/oxygen demand), in spite of 
abnormal and insufficient tumor vascularization (Levine, 
2007). Additionally, autophagy provides resistance to 
anoikis, a special type of apoptosis that cells activate 
following detachment from the basal lamina, a property 
that facilitates tumor cell evasion from primary sites, 
invasion, and spread (Fung et al., 2008). Cancer cell 
dormancy and chemotherapy resistance were also linked 
to the autophagic capacity of cells (Gewirtz, 2009). The link 
between cancer and autophagy is further supported by the 
fact that some autophagy-related proteins also function as 
tumor suppressors or oncogenes (Gozuacik and Kimchi, 
2004; Morselli et al., 2009). In the following sections, we 
will discuss relevant literature and provide examples about 
the dual role of autophagy in cancer. 
4.1. Tumor suppressor role of autophagy
Defective autophagy was linked to several diseases, 
including cancer. Manipulation of autophagy genes in 
mice provided important clues as to the role of autophagy 
in cancer. For example, Atg4C-deficient mice not only 
have reduced starvation-related autophagy responses but 
also have increased susceptibility to the development of 
chemical carcinogen-induced fibrosarcomas (Marino 
et al., 2007). Mice with heterozygous Atg5 deletion, as 
well as mice with homozygous Atg7 deletion, developed 
benign liver adenomas (Takamura et al., 2011). Mice 
with a heterozygous disruption of the Beclin 1 gene 
(mouse ortholog of human BECN1) were generated 
by 2 independent laboratories (Qu et al., 2003; Yue et 
al., 2003). In both lines of genetically modified mice, 
Beclin 1 haploinsufficiency resulted in the formation of 
spontaneous tumors, including lung adenocarcinomas, 
hepatocellular carcinomas (HCCs), and lymphomas. The 
tendency to develop HCCs was increased when these 
mice were crossed with liver cancer-prone mice (Yue et 
al., 2003). Similarly, Uvrag or Bif1 heterozygous deletion 
also enhanced cancer susceptibility in mice (Liang et al., 
2006; Takahashi et al., 2007). These findings underline 
that tumor suppression is a shared property of different 
components of the autophagic pathway, rather than being 
a phenotype unique to the disruption of an individual 
autophagy gene. In line with these findings, mutations 
or deletions of several autophagy genes were reported in 
human cancers (see below). 
Accumulating data in the literature provide clues 
about how suppression of autophagy may lead to cancer. 
It is now well established that autophagy-defective 
cells cannot recycle organelles, cytoplasmic long-lived 
proteins, and protein aggregates. As a result, these cells 
accumulate damaged mitochondria, and their cytoplasms 
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are packed with deposits of p62 protein (and possibly 
other proteins). Hence, together with energy problems 
and metabolic stress, autophagy-defective cells show a 
remarkable increase in ROS levels, making them prone 
to DNA double-strand breaks, gene amplifications, and 
chromosome rearrangements (Mathew et al., 2007, 2009a). 
These results were confirmed both in 3D culture assays and 
in vivo in mice (Karantza-Wadsworth et al., 2007; Mathew 
et al., 2009a). Moreover, there is evidence that autophagy 
deficiency and p62 deregulation might be associated 
with the suppression of the canonical NFKB pathway 
and accelerated oncogenesis through the noncanonical 
pathway (Mathew et al., 2009a). Thus, autophagy acts 
as a protection mechanisms against proteotoxicity and 
genotoxic stress, and it helps maintain genome integrity 
and proper cellular signaling.
During cancer formation, cells generally inactivate 
apoptosis pathways and become less sensitive to apoptotic 
stimuli. In a context where apoptosis pathways were 
blocked, autophagy incompetent cells were reported to be 
more prone to undergo necrosis during metabolic stress, a 
cell death that results in the extracellular release of cellular 
contents and that triggers inflammatory responses. 
For example, activation of autophagy-suppressor AKT 
pathway or loss of a Beclin 1 allele in combination with 
the overexpression of BCL2 made cells more susceptible 
to necrosis during metabolic stress and resulted in 
inflammatory cell infiltration to tissues in vivo (Degenhardt 
et al., 2006). In fact, necrosis and inflammation correlate 
with enhanced tumorigenic potential in solid tumors. 
Hence, limitation of metabolic stress and prevention 
of necrotic cell death and inflammation may also be 
Figure 2. Dual role of autophagy in cancer. Due to genomic instability or abnormalities in oncogene/tumor suppressors, some cells 
may change their character and start to grow abnormally. These genetic instabilities may occur due to dysfunctional mitochondria 
and increased production of ROS in the cell. At early stages of the cancer, cells can eliminate the dysfunctional mitochondria by a 
selective type of autophagy called mitophagy. Oncogene-induced senescence may also be another mechanism to restrict cell growth and 
proliferation during oncogenic stress. Moreover, autophagy-related cell death can prevent cancer cell growth. On the other hand, at later 
stages of cancer, autophagy can act as a survival pathway to support tumor growth under metabolic stresses such as hypoxia or nutrient 
deprivation and maintain mitochondria function. Moreover, autophagy provides resistance to anoikis (detachment-induced apoptosis) 
and facilitates invasion, metastasis, and cancer cell dormancy. 
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factors contributing to the tumor-suppressor function of 
autophagy in vivo. 
Senescence is the status of cell cycle arrest with an 
active metabolism. Together with apoptosis induction, 
senescence is 1 of the 2 major anticancer mechanisms 
that are activated in normal cells in response to oncogene 
activation. In an interesting study, Young et al. (2009) 
showed that autophagy was activated in human diploid 
fibroblast cells during oncogene-induced senescence. 
Indeed, expression of oncogenic Ras rapidly activated 
autophagy in this system. Autophagy was required for the 
establishment of senescence arrest since RNAi-mediated 
depletion of Atg5 or Atg7 facilitated the ability of cells 
to escape from senescence and delayed senescence-
associated cytokine production (Young et al., 2009). In line 
with these results, in an in vivo model, senescence marker-
positive regions of tumor tissues contained more LC3-
positive puncta than proliferative regions, indicating that 
autophagic activity was higher in senescent cells (Young 
et al., 2009). These results indicate that oncogene-induced 
senescence may be another autophagy-related tumor-
suppressor mechanism that restricts normal cell growth 
and proliferation during oncogenic stress, preventing 
further genomic impairments. 
In contrast with its role as a stress response mechanism 
for cell survival, under certain in vitro contexts and in vivo 
conditions, autophagy might lead to cell death (Gozuacik 
and Kimchi, 2007). Several tumor suppressor and death-
related proteins, including DAPK, DRP1, ZIP, and a 
p19ARF form, triggered nonapoptotic and autophagy-
dependent cell death (Inbal et al., 2002; Shani et al., 2004; 
Reef et al., 2006; Gozuacik et al., 2008). In analogy with 
apoptosis, it was proposed that a defect in “autophagy-
related cell death” or “autophagic cell death” could 
contribute to cancer formation (Gozuacik and Kimchi, 
2007). For example, introduction of oncogenic H-Ras 
protein to nontransformed cells was shown to activate 
nonapoptotic cell death with autophagic characteristics 
(Elgendy et al., 2011). In this way, autophagy was shown to 
block clonogenic survival of transformed cells and prevent 
tumor formation. H-Ras-induced autophagic cell death 
was blocked by silencing the BH3-only protein NOXA or 
autophagy protein BECN1. BCL2 proteins that sequester 
BECN1 were also shown to block the effect (Elgendy et 
al., 2011). 
4.2. Tumor-promoting role of autophagy
In early stages of carcinogenesis, autophagy seems to 
mainly exert a tumor-suppressor function. However, in 
established tumors, autophagy might act as a mechanism 
supporting the survival of cancer cells. Cancer cells face a 
number of stress factors, including hypoxia, pH changes, 
growth factor deprivation, nutrient insufficiency and 
irregular nutrient support, and inappropriate extracellular 
matrix signals. To cope with these harsh and unfavorable 
conditions, cancer cells activate autophagy, allowing 
them to maintain cellular biosynthesis and ATP levels 
and survive. Indeed, cancer cells in the interior parts of 
solid tumors, where the above-mentioned conditions are 
more dramatic, had especially elevated levels of autophagy 
compared with those at tumor margins (Degenhardt et 
al., 2006). In in vivo models of cancer, autophagy helps 
sustain tumor metabolism, maintains mitochondrial 
quality and mitochondria function, controls reactive 
oxygen production, and allows nutrient recycling (Guo et 
al., 2013a). For example, autophagic activity was elevated 
in pancreas cancer cells and in tumor specimens, and 
suppression of autophagy resulted in tumor regression 
and extended lifespan in pancreas cancer xenografts 
and genetic mouse models (Yang et al., 2011). In K-Ras-
driven transgenic cancer models, autophagy supported 
tumor survival and growth by preserving mitochondrial 
energy production and metabolism (Guo et al., 2011). 
Interestingly, in lung tumors developing on a mutant 
K-Ras background, progression of tumors from adenomas 
to adenocarcinomas was blocked, and knockout of the 
autophagy gene Atg7 in this context led to the formation 
of benign oncocytomas instead (Guo et al., 2013a). 
Similarly, autophagy-deficiency impaired tumor growth 
in B-Raf-driven lung tumors (Strohecker et al., 2013). In 
a mammary-specific Palb2 gene knock-out mouse model 
of breast cancer, autophagy impairment by allelic loss of 
Beclin 1 delayed tumor development in a p53-dependent 
manner (Huo et al., 2013). 
Moreover, autophagy was reported to promote tumor 
invasion. In epithelial cells transformed with oncogenic 
Ras, depletion of autophagy genes resulted in a decrease in 
motility and invasion capacity in 3-dimensional cultures 
and reduced pulmonary metastases in vivo (Lock et al., 
2014). Autophagic activity was also important for the 
survival of dormant cancer cells in vivo (Lu et al., 2008). 
All these data underline the importance of autophagy 
in the maintenance of tumor metabolism and progression 
to malignancy, and even metastasis, in different biological 
scenarios.
4.3. Cancer-related changes in autophagy genes/proteins
Accumulating data in the literature provides evidence 
that genes and proteins of the autophagy machinery 
and other autophagy regulators might be mutated and/
or dysregulated in cancer (Table). In line with the 
experimental data, studies with human tumor specimens 
and comparisons with normal tissues point to a context 
of the tumor-grade- and tumor-type-dependent nature of 
the autophagy/cancer relation. Most of these studies are 
correlative; nevertheless, autophagy gene mRNA and/or 
protein expression changes and mutations were observed 
in different tumor series. 
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Table. Cancer-related changes in core autophagy genes and proteins.
Gene/protein Cancer-related changes References
ULK1 (Atg1)
Increased expression in esophageal squamous cell carcinomas and hepatocellular 
carcinomas
Reduced expression in breast cancers 
(Jiang et al., 2011; Tang et al., 2012; Xu et al., 2013; Jiang 
et al., 2014) 
ATG2B Frameshift mutations in gastric cancers and colorectal cancers (Kang et al., 2009)
ATG3
Reduced expression in myelodysplastic syndrome patients with leukemic 
evolution
(Ma et al., 2013a)
ATG4B Increased expression in CD34(+) chronic myeloid leukemia cells (Rothe et al., 2014)
ATG5
Low-frequency frameshift mutations in gastric cancers and colorectal cancers 
Genetic variations may correlate with thyroid carcinoma susceptibility 
Reduced expression in natural killer cells and in gastric, colorectal, and 
hepatocellular carcinomas
Increased expression in CD34(+) chronic myeloid leukemia cells
(Iqbal et al., 2009; Kang et al., 2009; An et al., 2011; Cho 
et al., 2012; Plantinga et al., 2014; Rao et al., 2014; Rothe 
et al., 2014)
BECN1 (Atg6)
Reduced expression in breast cancers, nonsmall cell lung cancers, renal clear 
cell carcinomas, brain tumors, cervical squamous cell carcinomas, hepatocellular 
carcinomas, ovarian cancers, osteosarcomas, melanomas, and glioblastomas 
Mutations in ovarian cancers, human breast cancers, prostate cancers 
Reduced expression due to gene methylation in breast cancers 
Increased expression in CD34(+) chronic myeloid leukemia cells, colon cancers 
(stage IIIB), non-Hodgkin lymphomas, cholangiocarcinomas
(Russell et al., 1990; Futreal et al., 1992; Cliby et al., 1993; 
Saito et al., 1993; Tangir et al., 1996; Aita et al., 1999; Liang 
et al., 1999; Qu et al., 2003; Wang et al., 2006; Lee et al., 
2007; Miracco et al., 2007 ; Ding et al., 2008; Liu et al., 
2008; Shen et al., 2008 ; Li et al., 2009; Zhang et al., 2009; 
Huang JJ et al., 2010; Huang X et al., 2010; Koukourakis et 
al., 2010; Lazova et al., 2010; Li Z et al., 2010; Miracco et 
al., 2010; Nicotra et al., 2010; Dong et al., 2011; Liu et al., 
2011; Sivridis et al., 2011; Jiang et al., 2012; Choi et al., 
2013; Deng et al., 2013; Dong et al., 2013; Laddha et al., 
2014; Rothe et al., 2014)
LC3 (Atg8)
Increased expression in triple-negative breast cancers, colorectal cancers, 
gastrointestinal cancers, pancreatic cancers, and non-Hodgkin lymphomas 
Reduced expression in lung cancers and nonsmall cell lung cancers, melanomas, 
and glioblastomas
(Sato et al., 2007; Fujii et al., 2008; Liu et al., 2008; 
Yoshioka et al., 2008; Othman et al., 2009; Huang X et al., 
2010; Miracco et al., 2010; Nicotra et al., 2010; Sivridis et 
al., 2011; Jiang et al., 2012; Choi et al., 2013)
ATG9B Frameshift mutations in gastric cancers and colorectal cancers (Kang et al., 2009)
ATG10
Increased expression in colorectal cancers is associated with metastasis 
Genetic variations may correlate with breast cancer susceptibility 
(Jo et al., 2012; Qin et al., 2013)
ATG12 Frameshift mutations in gastric cancers and colorectal cancers (Kang et al., 2009)
ATG16L1
Genetic variations may correlate with colorectal cancers and thyroid carcinoma 
susceptibility
Increased expression in oral squamous cell carcinomas
(Nomura et al., 2009; Huijbers et al., 2012; Nicoli et al., 
2014)
UVRAG Mutations in colorectal cancers and gastric cancers
(Ionov et al., 2004; Liang et al., 2006; Kim MS et al., 2008; 
Knaevelsrud et al., 2010)
BIF1
Reduced expression in colorectal cancers, pancreatic ductal adenocarcinomas, 
gastric cancers, urinary bladder cancers, gallbladder cancers, and prostate cancers
(Lee et al., 2006; Takahashi et al., 2007; Coppola et al., 
2008a; Coppola et al., 2008b; Kim SY et al., 2008; Coppola 
et al., 2011; Ko et al., 2013; Takahashi et al., 2013)
PIK3C3/hVPS34
Differentially expressed between the TEL/AML1-positive and negative acute 
lymphocytic leukemia groups
SNP associated with esophageal squamous cell carcinomas
(Hu et al., 2005; Gandemer et al., 2007)
GABARAP
Increased expression in colorectal carcinomas and benign and malignant thyroid 
tumors
Reduced expression in neuroblastomas and breast cancers
(Roberts et al., 2004; Klebig et al., 2005; Roberts et al., 
2009; Miao et al., 2010)
GABARAPL1
Reduced expression in lymph node-positive high-grade breast cancers, acute 
myelocytic leukemias, and hepatocellular carcinomas
(Berthier et al., 2010; Brigger et al., 2013; Liu et al., 2014)
GABARAPL2 / 
GATE16
Reduced expression in acute myelocytic leukemias (Brigger et al., 2013)
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A direct functional link between autophagy and cancer 
was shown for the first time by the identification of BECN1 
as a haploinsufficient tumor suppressor, a gene that is 
monoallelically deleted in a large population of ovarian, 
breast, and prostate cancers (Liang et al., 1999; Qu et al., 
2003). For example, out of 17 pairs of matched normal 
breast and breast carcinoma tissues, 15 sample pairs had 
higher levels of BECN1 in normal than in tumor breast 
tissue. Furthermore, in an overlapping tumor series, 
analysis by immunohistochemistry revealed a significant 
decrease in BECN1 protein levels in 18 of 32 breast 
carcinoma cells compared with normal breast lobular of 
ductal epithelial cells (Liang et al., 1999). In line with these 
results, expression of BECN1 was reported to be reduced 
in breast cancers, nonsmall cell lung cancers, renal clear 
cell carcinomas, brain tumors, cervical squamous cell 
carcinomas, hepatocellular carcinomas, ovarian cancers, 
osteosarcomas, melanomas, and glioblastomas (Russell et 
al., 1990; Futreal et al., 1992; Cliby et al., 1993; Saito et al., 
1993; Tangir et al., 1996; Aita et al., 1999; Liang et al., 1999; 
Qu et al., 2003; Wang et al., 2006; Lee et al., 2007; Miracco 
et al., 2007; Ding et al., 2008; Liu et al., 2008; Shen et al., 
2008; Li et al., 2009; Zhang et al., 2009; Huang JJ et al., 2010; 
Huang X et al., 2010; Koukourakis et al., 2010; Lazova et 
al., 2010; Li Z et al., 2010; Miracco et al., 2010; Nicotra et 
al., 2010; Dong et al., 2011; Liu et al., 2011; Sivridis et al., 
2011; Jiang et al., 2012; Choi et al., 2013; Deng et al., 2013; 
Dong et al., 2013; Laddha et al., 2014; Rothe et al., 2014).
The key component of BECN1 protein complexes, the 
PI3-kinase hVPS34/PIK3C3, was differentially expressed 
between the TEL/AML1-positive and -negative acute 
lymphocytic leukemia groups (Gandemer et al., 2007). 
Moreover, a single nucleotide polymorphism (SNP) in 
the hVPS34/PIK3C3 gene was found to be associated with 
esophageal squamous cell carcinomas (Hu et al., 2005).
UVRAG, a regulator of BECN1 complexes, was 
monoallelically deleted in human colon cancers (Liang et 
al., 2006) and gastric carcinomas (Kim MS et al., 2008). 
Additionally, a polyadenine tract in the UVRAG gene (A10 
in exon 8) was reported as a target of frameshift mutations, 
leading to a decrease in autophagic capacity of colon and 
gastric cancers with microsatellite instability (Ionov et al., 
2004; Knaevelsrud et al., 2010).
Expression of another autophagy gene, ULK1, was 
downregulated in breast cancers and this event was closely 
related to the progression of the disease (Tang et al., 2012). 
In contrast, ULK1 was overexpressed in hepatocellular 
carcinomas (Xu et al., 2013) and in esophageal squamous 
carcinomas (Jiang et al., 2011, 2014). Another component 
of the ULK1 complex, FIP200, was also analyzed in tumor 
samples. Loss of heterozygosity of FIP200 was associated 
with breast cancer in 20% of cases (Chano et al., 2002).
Other autophagy-related genes and proteins were 
also reported to be subject to cancer-related changes. 
For example, frameshift mutations of the key autophagy 
gene ATG5 were observed in gastric cancer and colorectal 
cancer samples (Kang et al., 2009). Similarly, a SNP in the 
ATG5 gene was associated with increased susceptibility 
to nonmedullary thyroid carcinoma (Plantinga et al., 
2014). Loss of ATG5 expression was observed in gastric, 
colorectal, and hepatocellular carcinomas (An et al., 
2011; Cho et al., 2012). Moreover, in natural killer cell 
malignancies, deletion of the 6q21 region that also includes 
the ATG5 gene was shown to lead to a decrease in gene 
expression (Iqbal et al., 2009). However, ATG5 expression 
was increased in CD34(+) chronic myeloid leukemia cells 
(Rothe et al., 2014).
LC3 proteins that play a critical role in autophagosome 
formation and elongation were also analyzed in tumors. 
For example, while the expression of GABARAP in 
colorectal and thyroid carcinomas was upregulated, it 
was downregulated in neuroblastomas and breast cancers 
(Roberts et al., 2004; Klebig et al., 2005; Roberts et al., 
2009; Miao et al., 2010). Moreover, GABARAPL1 was 
found to be downregulated in acute myelocytic leukemias, 
hepatocellular carcinomas, and lymph node-positive 
high-grade breast cancers (Berthier et al., 2010; Brigger 
et al., 2013; Liu et al., 2014). Likewise, the expression of 
GABARAPL2/GATE16 was decreased in acute myelocytic 
leukemia cells (Brigger et al., 2013).
The above-mentioned analyses and others indicate 
a strong correlation between cancer formation and 
autophagy-related changes. Strikingly, in many cases, 
a downregulation of an autophagy gene was reported 
in tumor samples rather than an amplification and 
an upregulation (Table). For example, ULK1, BECN1, 
and GABARAPL1 expression levels were reported to 
be decreased in independent studies performed with 
breast cancer specimens (Liang et al., 1999; Wang et al., 
2006; Miracco et al., 2007; Ding et al., 2008; Liu et al., 
2008; Shen et al., 2008; Berthier et al., 2010; Huang X et 
al., 2010; Li Z et al., 2010; Miracco et al., 2010; Jiang et 
al., 2011; Tang et al., 2012; Brigger et al., 2013; Liu et al., 
2014). Moreover, reduced expression of several autophagy 
genes/proteins were observed in gastric, colorectal, renal, 
pancreas, bladder, and prostate cancers and hepatocellular 
carcinomas, neuroblastomas, some leukemias, etc. 
Surprisingly, besides long-range chromosomal 
abnormalities, autophagy gene-specific mutations and 
rearrangements were not frequently encountered, leading 
some groups to question the functional relevance of these 
observations (Laddha et al., 2014). However, several 
SNP polymorphisms were found in ATG genes and they 
correlated with cancer susceptibility. These results are 
in line with the tumor-suppressor role of autophagy in 
early stages of cancer formation. In light of experimental 
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preclinical studies, it is highly probable that the described 
changes in autophagy-related genes and proteins directly 
contribute to tumor formation through dysregulation of 
autophagic activities. 
5. Autophagy and anticancer therapies
Autophagy upregulation was observed in response 
to anticancer treatments, i.e. radiation therapy, 
chemotherapy, and even molecular targeted therapies 
(Eberhart et al., 2013). Both cytoprotective and death-
inducing properties of autophagy were reported during 
chemotherapy or radiotherapy of cancer, and autophagic 
capacity of cancer cells seems to affect their response 
to anticancer treatments. In this section we will briefly 
summarize the role of autophagy in determining response 
to chemotherapy. In this context, modulation of autophagy 
offers the possibility of altering the course of treatments 
and affecting therapeutic outcomes. Depending on the 
tumor type and the treatment approach, autophagy 
inhibition or activation might reestablish sensitivity to 
therapeutic agents and overcome treatment resistance. 
Autophagy inhibitors that are commonly used in 
experimental studies fall into 2 major categories: early-
stage inhibitors targeting the hVPS34-containing PI3K 
complex and interfering with autophagosome formation 
include, and 3-methyladenine (3-MA), wortmannin, and 
LY294002. Late-stage inhibitors, including antimalarial 
drugs chloroquine (CQ) and hydroxychloroquine (HCQ) 
and late-endosomal/lysosomal H+ pump inhibitor 
bafilomycin A1, block autolysosome formation and 
lysosomal degradation. Commonly used autophagy 
activators include rapamycin and its derivatives.
5.1. Autophagy inhibition in anticancer therapy
There are several studies showing that combining 
pharmacologic inhibition of autophagy with current 
anticancer therapies might improve the clinical efficacy of 
chemotherapeutic agents (Livesey et al., 2009). 
For example, 3-MA was shown to potentiate cell death 
induced by SAHA (suberoylanilide hydroxamic acid, a 
histone deacetylase inhibitor) in chronic myelogenous 
leukemia (CML) cells (Carew et al., 2007). In colon cancer 
xenografts, autophagy inhibition by 3-MA was shown to 
increase apoptosis induction by 5-fluorouracil and led to 
tumor regression (Li J et al., 2010). Celastrol, a quinone 
methide triterpenoid, could induce apoptosis in pancreatic 
cancer cells, and when the therapy was combined with 
3-MA, the therapeutic effect of celastrol was improved 
both in vitro and in vivo (Zhao et al., 2014). 
On the other hand, late-stage inhibitors CQ and HCQ 
increased cytotoxic effects of p53 and alkylating agents in 
a Myc-induced mouse model of lymphoma (Amaravadi 
et al., 2007). When CQ was combined with vorinostat, an 
HDAC inhibitor, a significant reduction in tumor burden 
and an increase in apoptosis was observed in a colon cancer 
xenograft model (Carew et al., 2010). Similarly, therapeutic 
efficacy of the Src inhibitor saracatinib was increased 
when combined with CQ in a prostate cancer xenograft 
mouse model (Wu et al., 2010). Tyrosine kinase inhibitor 
imatinib-mediated death of CML cells was increased 
following inhibition of autophagy using CQ (Bellodi et 
al., 2009). Moreover, CQ enhanced the effect of SAHA 
in both imatinib-sensitive and imatinib-resistant lines of 
CML (Carew et al., 2007). Similarly, autophagy inhibition 
by HCQ enhanced therapeutic responses of breast cancer 
cells to anthracycline epirubicin both in vitro and in vivo 
(Chittaranjan et al., 2014). Moreover, bafilomycin A1 was 
found to enhance antitumor effects of irradiation, arsenic 
trioxide, or Akt inhibitors (Paglin et al., 2001; Kanzawa et 
al., 2003; Degtyarev et al., 2008). 
All of these studies and others underline the potential 
of autophagy inhibition as a treatment strategy. 
5.2. Autophagy activation in anticancer therapy
In contrast with the above-mentioned examples, induction 
of autophagy by anticancer agents or autophagy-inducing 
compounds was reported to improve cancer therapy in 
certain contexts. Autophagy induction by drugs alone or in 
combination with autophagy inducers such as rapamycin 
derivatives or general mTOR inhibitors was shown to 
potentiate anticancer effects in these studies. 
Rapamycin and its analogs (rapalogs), temsirolimus 
(CCI-779), everolimus (RAD-001), and deforolimus 
(AP-23573), selectively target the mTORC1 complex and 
stimulate autophagy. Rapalogs were tested as anticancer 
agents alone and in combination with chemotherapy or 
radiotherapy. For example, RAD001 induced autophagy 
and sensitized papillary thyroid cancer cells to doxorubicin 
treatment and radiotherapy (Lin et al., 2010). In line 
with this, rapamycin and its derivatives showed additive 
or synergistic effects when used in combination with 
paclitaxel, carboplatin, cisplatin, vinorelbine, doxorubicin, 
and camptothecin (Geoerger et al., 2001; Grunwald et al., 
2002; Shi et al., 2002; Mondesire et al., 2004; Pandya et al., 
2007; Steelman et al., 2008). 
mTORC2, the other complex including mTOR kinase 
and that is resistant to rapamycin and its derivatives, 
also contributes to autophagy regulation, and inhibitors 
targeting both mTOR complexes (mTORC1 and 
mTORC2), including Torin1, PP242, AZD8055, and WYE-
125132, were also used to improve the efficacy of cancer 
therapy. For example, AZD8055 is an orally available ATP-
competitive inhibitor of mTOR kinase activity. AZD8055 
showed significant antitumor activity and led to tumor 
growth reduction in glioma, prostate, colon, and uterus 
human tumor xenografts (Chresta et al., 2010). Another 
potent mTOR inhibitor, WYE-125132, was shown to 
exhibit strong antitumor activity against breast, glioma, 
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lung, and renal cancer cells in vitro and against breast and 
lung tumors in vivo (Yu et al., 2010). 
Several other anticancer molecules were shown to 
activate autophagy and cell death in cancer cells. Strikingly, 
cell death could be blocked by chemical or genetic 
inhibition of autophagy in many cases (Eberhart et al., 
2013). For example, treatment of breast cancer cells with 
antimetabolite pemetrexed killed them, and cell death was 
blocked by 3-MA or by the knockdown of BECN1 (Bareford 
et al., 2011). Combination of pemetrexed with rapamycin 
potentiated pemetrexed toxicity in multiple tumor cell 
types. In another example, autophagy inhibition by the 
knockdown of ATG5 or BECN1 significantly blocked the 
cytotoxicity of an ERBB1/ERBB2 inhibitor (lapatinib) and 
BH3 domain antagonist obatoclax combination (Martin et 
al., 2009). Similarly, EGFR inhibitor cetuximab activated 
autophagy and cell death in combination with rapamycin 
(Li X et al., 2010). Similarly, BCR-ABL inhibitor imatinib 
induced cytotoxicity that could be attenuated by the 
inhibition of autophagy (Shingu et al., 2009).
All of these studies indicate that overactivation of 
autophagy in cancer may also show cytotoxic effects 
depending on cancer type and context. 
6. Conclusion 
Autophagy is one of the most important and basic cellular 
mechanisms. Not surprisingly, the basic machinery of 
autophagy has been preserved from yeast to man with little 
variation. Being a central event in the preservation of cellular 
and organismal homeostasis, abnormalities of autophagy 
result in the disturbance of key cellular events, including 
catabolism/metabolism balance, energy equilibrium, ROS 
control, and organelle recycling. Consequently, autophagy 
abnormalities cause or exacerbate pathologies.
Autophagy plays a central role in cellular responses 
to various types of stress, including exposure to toxins 
and carcinogens, genotoxicity and DNA damage, 
inflammation-related cytokines and lymphokines, viruses, 
and even oncogene activation, and it helps the cell to 
preserve proper protein function, mitochondrial function, 
and genomic health. Under these conditions, autophagy 
might contribute to critical “cell proliferation versus cycle 
arrest” and “cell survival versus cell death” decisions. 
Additionally, autophagy was implicated in events that 
modulate immune surveillance through its role in antigen 
presentation, T and B cell maturation, and inflammation 
(Munz, 2009; Carneiro and Travassos, 2013; Ma et al., 
2013b; Viry et al., 2014). All of these functions are in line 
with a tumor-suppressor role of autophagy during early 
stages of cancer formation (Figure 2).  
On the other hand, in established cancers and especially 
solid tumors, autophagy may act as a major metabolic 
stress response, supporting the survival of cancerous 
cells facing harsh conditions such as nutrient and growth 
factor deprivation, hypoxia, ROS accumulation, and 
acidosis. Rapidly dividing tumor cells from animal models 
of cancer might even become “addicted to autophagy” 
and their metabolism and survival might heavily rely 
on it (White, 2013). These conditions might even be 
exacerbated following detachment from primary tumor 
sites during invasion, metastasis, and dormancy. Thus, 
during later stages of cancer, autophagy seems work in 
favor of tumor growth and spread (Figure 2). Strikingly, 
results of studies analyzing cancer cells and tissues from 
patients mainly showed a decrease in autophagy-related 
gene/protein expression, even though the opposite 
was observed for some tumor types (Table). A general 
decrease in the autophagic capacity of cells was reported 
in transformed cells (Gozuacik and Kimchi, 2004). It is 
thus possible that cancer-prone cells acquire autophagy-
dampening changes to overcome autophagy-related tumor 
suppression in the early phases of transformation, while 
preserving the capacity to upregulate stress-induced 
autophagy when faced with harsh conditions found in the 
tumor environment. 
Autophagy has important implications for cancer 
treatment. Most cancer treatment strategies (chemotherapy, 
radiotherapy, and new-line targeted molecules) were 
shown to activate autophagy in target cells. In line with 
the prosurvival role of autophagy in established cancers, 
autophagy inhibitor drugs, alone or in combination with 
cancer therapy, were shown to improve the efficacy of 
treatment approaches in many cases. However, in some 
other cases, activation of excessive autophagy was shown 
to potentiate the anticancer properties of the treatments. 
In some studies, autophagy activator rapalogs and general 
mTOR inhibitors were shown to increase the efficacy of 
chemotherapy. It should also be mentioned that autophagy 
inhibition in the context of tumor treatment was mainly 
achieved using lysosomotropic agents such as CQ and 
HCQ. In addition to autophagy inhibition, these agents 
were shown to disrupt lysosomal integrity and activate 
apoptosis or nonapoptotic cell death (Eberhart et al., 2013 
and references therein). It is thus possible that additive or 
synergistic effects of anticancer regimens might not only 
depend on autophagy modulation effects of the above-
mentioned drugs. Another concern is related to the tumor-
suppressor role of autophagy in normal tissues: to avoid 
side effects in normal cells and tissues following systemic 
administration of autophagy drugs, the effects of these 
treatment modalities on normal, noncancerous tissues of 
cancer subjects should be thoroughly documented during 
the development of more specific autophagy-inhibitor or 
-activator anticancer drugs.
The autophagy field gained momentum with 
discoveries involving this basic biological event in human 
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diseases, including cancer. However, we are just beginning 
to appreciate the relevance and importance of autophagy 
in cancer biology, and further studies are required. Data 
from several independent groups indicate that autophagy 
modulation has big potential as a novel cancer treatment 
approach. Therefore, advances in the field will surely have 
implications beyond the lab bench and will very probably 
have an impact in the near future on the way malignancies 
will be handled by clinicians. 
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